The latest price target for Evolent Health (NYSE:EVH) was reported by Oppenheimer on March 2, 2026. The analyst firm set a price target for $6.00 expecting EVH to rise to within 12 months (a possible 89.27% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Evolent Health (NYSE:EVH) was provided by Oppenheimer, and Evolent Health maintained their outperform rating.

The last upgrade for Evolent Health Inc happened on August 9, 2024 when Truist Securities raised their price target to $33. Truist Securities previously had a hold for Evolent Health Inc.

The last downgrade for Evolent Health Inc happened on February 25, 2026 when Keybanc changed their price target from N/A to N/A for Evolent Health Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evolent Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evolent Health was filed on March 2, 2026 so you should expect the next rating to be made available sometime around March 2, 2027.

While ratings are subjective and will change, the latest Evolent Health (EVH) rating was a maintained with a price target of $12.00 to $6.00. The current price Evolent Health (EVH) is trading at is $3.17, which is out of the analyst’s predicted range.